There might be additional benefit on clinical outcomes from adjunctive colistimethate sodium inhalation as therapy for multidrug resistant Gram-negative ventilator-associated pneumonia.
Besides, early antibiotics intervention might be benefit for patients with ventilator-associated tracheobronchitis or lower airway colonization with multidrug resistant Gram-negative bacteria.
Study Type
OBSERVATIONAL
Enrollment
49
National Taiwan University Hospital
Taipei, Taiwan
clinical cure rate
including clinical improvement and microbiological outcome(eradication of the pathogen as no growth of the pathogen in the final culture of specimens during the entire hospitalization)
Time frame: From date of starting colistimethate sodium to 28th days or til discharge from hospital, whichever came first, assessed up to 28 days
intensive care unit stay
Time frame: From date of starting colistimethate sodium to discharge date of intensive care unit, assessed up to 3 months
hospital stay
Time frame: From date of starting colistimethate sodium to discharge date of hospital, assessed up to 3 months
all cause mortality
Time frame: From date of starting colistimethate sodium to 28th days or til death, whichever came first, assessed up to 28 days
ventilator-associated pneumonia-related mortality
Time frame: Death that occurred during the colistimethate sodium treatment period when the signs of pneumonia remained and as death due to septic shock, assessed up to 28 days
microbiologic eradication in colonization patients
Time frame: From date of starting colistimethate sodium to 28th days or til discharge from hospital, whichever came first, assessed up to 28 days
ventilator-associated pneumonia rate
Time frame: From date of starting colistimethate sodium to discharge date of hospital, assessed up to 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.